Professional Background:

Kristof Zarschler completed his university studies in Biology at the
Technische Universität Dresden (TUD), Germany in 2005 and received his PhD
with distinction from the Department of Nanobiotechnology at the University
of Natural Resources and Life Science Vienna (BOKU), Austria in 2009. Before
joining the Institute of Radiopharmaceutical Cancer Research (IRCR) of the
Helmholtz-Zentrum Dresden-Rossendorf (HZDR) in 2011, Kristof was a
postdoctoral research associate at the Institute for Genetics of the TUD
(2010-2011). Kristof is currently research associate at the Department of
Medicinal Radiochemistry of the IRCR working on the biological evaluation
and modulation of targeted, radiometal-based bioconjugates.

Research Interests:

Kristof’s research focus is on the in-depth biological characterization and
pharmacological evaluation of novel radiopharmaceuticals based on small
molecules, peptides and antibody derivatives. Hereby, the individual
building blocks (e.g. radiometals, chelators) as well as the conjugates as a
whole are analyzed in depth regarding their in vitro stability, their
effects on cell signaling and health as well as their multifaceted
interactions with biomolecules and cells. Our fundamental aim is to
understand the biology of such materials and to shed light on involved
molecular mechanisms and use the knowledge gained for rationally improving
their design in that respect. Building up on these studies, we are also
working on precise engineering and tailoring of different kinds of
bioconjugates for their application as diagnostic tools and therapeutic
agents.